Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice.

002 antibody Cancer cachexia Fn14 receptor TWEAK [18F]FDG PET

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 16 03 2024
accepted: 04 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

Cachexia is a complex syndrome characterized by unintentional weight loss, progressive muscle wasting and loss of appetite. Anti-Fn14 antibody (mAb 002) targets the TWEAK receptor (Fn14) in murine models of cancer cachexia and can extend the lifespan of mice by restoring the body weight of mice. Here, we investigated glucose metabolic changes in murine models of cachexia via [ [ [ Our results demonstrate that Fn14 receptor activation is linked to glucose metabolism of cachexia-inducing tumours.

Identifiants

DOI: 10.1007/s00259-024-06836-1 PMID: 39060375
pubmed: 39060375
doi: 10.1007/s00259-024-06836-1
pii: 10.1007/s00259-024-06836-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Hopkinson JB, Wright DN, McDonald JW, Corner JL. The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage. 2006;32:322–31.
doi: 10.1016/j.jpainsymman.2006.05.012 pubmed: 17000349
Poole K, Froggatt K. Loss of weight and loss of appetite in advanced cancer: a problem for the patient, the carer, or the health professional? Palliat Med. 2002;16:499–506.
doi: 10.1191/0269216302pm593oa pubmed: 12465697
Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer Cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4:849–60.
doi: 10.1016/j.trecan.2018.10.001 pubmed: 30470306
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.
doi: 10.1016/j.clnu.2008.06.013 pubmed: 18718696
Rowland KM Jr., Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996;14:135–41.
doi: 10.1200/JCO.1996.14.1.135 pubmed: 8558188
Lok C. Cachexia: the last illness. Nature. 2015;528:182–3.
doi: 10.1038/528182a pubmed: 26659165
Cao Z, Zhao K, Jose I, Hoogenraad NJ, Osellame LD. Biomarkers for Cancer Cachexia: a Mini Review. Int J Mol Sci. 2021; 22.
Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev. 2011;244:99–114.
doi: 10.1111/j.1600-065X.2011.01054.x pubmed: 22017434
Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411–25.
doi: 10.1038/nrd2488 pubmed: 18404150 pmcid: 3018765
Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem. 1999;274:8455–9.
doi: 10.1074/jbc.274.13.8455 pubmed: 10085077
Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest. 2005;115:2330–40.
doi: 10.1172/JCI23486 pubmed: 16110324 pmcid: 1187931
Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol. 2008;182:171–84.
doi: 10.1083/jcb.200801010 pubmed: 18606850 pmcid: 2447903
Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 2012;22:557–66.
doi: 10.1016/j.tcb.2012.08.001 pubmed: 22995730
Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.
doi: 10.1186/1476-4598-12-86 pubmed: 23915189 pmcid: 3750319
Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, et al. Targeting of Fn14 prevents Cancer-Induced Cachexia and Prolongs Survival. Cell. 2015;162:1365–78.
doi: 10.1016/j.cell.2015.08.031 pubmed: 26359988
Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012;26:711–23.
doi: 10.1016/j.beem.2012.05.003 pubmed: 23168274 pmcid: 3513836
Rich P. Chemiosmotic coupling: the cost of living. Nature. 2003;421:583.
doi: 10.1038/421583a pubmed: 12571574
Kiamanesh Z, Ayati N, Sadeghi R, Hawkes E, Lee ST, Scott AM. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2022;49:4661–76.
doi: 10.1007/s00259-022-05918-2 pubmed: 35932329 pmcid: 9606078
Murphy PS, Galette P, van der Aart J, Janiczek RL, Patel N, Brown A. The role of clinical imaging in oncology drug development: progress and new challenges. Br J Radiol. 2023: 20211126.
Penet MF, Gadiya MM, Krishnamachary B, Nimmagadda S, Pomper MG, Artemov D, et al. Metabolic signatures imaged in cancer-induced cachexia. Cancer Res. 2011;71:6948–56.
doi: 10.1158/0008-5472.CAN-11-1095 pubmed: 21948967 pmcid: 3217079
Olaechea S, Gannavarapu BS, Alvarez C, Gilmore A, Sarver B, Xie D, et al. Primary tumor Fluorine-18 fluorodeoxydglucose ((18)F-FDG) is Associated with Cancer-Associated Weight loss in Non-small Cell Lung Cancer (NSCLC) and portends worse survival. Front Oncol. 2022;12:900712.
doi: 10.3389/fonc.2022.900712 pubmed: 35814438 pmcid: 9263563
Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703–7.
doi: 10.1016/j.cell.2008.08.021 pubmed: 18775299
Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927–30.
doi: 10.1158/0008-5472.CAN-06-1501 pubmed: 16982728
Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the Tumor Microenvironment is a driver of Cancer Progression. Cell. 2015;162:1229–41.
doi: 10.1016/j.cell.2015.08.016 pubmed: 26321679 pmcid: 4864363
Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162:1217–28.
doi: 10.1016/j.cell.2015.08.012 pubmed: 26321681 pmcid: 4567953
Vyas S, Zaganjor E, Haigis MC. Mitochondria Cancer Cell. 2016;166:555–66.
Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. Mol Cell. 2016;61:667–76.
doi: 10.1016/j.molcel.2016.02.011 pubmed: 26942671 pmcid: 4779192

Auteurs

Ingrid Julienne Georgette Burvenich (IJG)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia.

Laura Danielle Osellame (LD)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia.
Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3083, Australia.

Angela Rigopoulos (A)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.

Nhi Huynh (N)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia.

Zhipeng Cao (Z)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, 3083, Australia.

Nicholas Johannes Hoogenraad (NJ)

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3083, Australia.

Andrew Mark Scott (AM)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Melbourne, Heidelberg, VIC, 3084, Australia. andrew.scott@onjcri.org.au.
School of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia. andrew.scott@onjcri.org.au.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, 3083, Australia. andrew.scott@onjcri.org.au.
Department of Medicine, University of Melbourne, Melbourne, VIC, 3052, Australia. andrew.scott@onjcri.org.au.
ORCID: 0000-0002-6656-295X

Classifications MeSH